Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | TDO2 | P48775 | 2/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.36 |
| ▸ | LCAT | P04180 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4153814 | 0.83 | CHRNB2 (0.43) | CHRM4SMN1; SMN2 | |
| SCHEMBL4158820 | 0.83 | CHRM4 (0.37) | NR1H2NR1H3CHRM4 | |
| SCHEMBL5341381 | 0.81 | PHGDH (0.39) | IDO1TDO2SLC6A9NOTUMLMNA | |
| SCHEMBL20549169 | 0.80 | RHOA (0.38) | IDO1TDO2SLC6A9 | |
| SCHEMBL23705807 | 0.80 | CHRM2 (0.51) | NR1H2NR1H3ACACBSLC6A9CHRM4 | |
| SCHEMBL3327045 | 0.79 | IDO1 (0.57) | IDO1TDO2LMNASMN1; SMN2CCR2 | |
| SCHEMBL5344877 | 0.78 | FFAR4 (0.36) | IDO1TDO2SLC6A9NOTUMLMNA | |
| SCHEMBL23706068 | 0.77 | RBP4 (0.43) | LMNASMN1; SMN2 | |
| SCHEMBL21224830 | 0.76 | SLC6A7 (0.40) | NOTUM | |
| SCHEMBL14159644 | 0.76 | CHRM4 (0.33) | CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563582-B2 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-20090208485-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090208485-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR5, ACKR3, CXCR3 | NR1H2 159/4885NR1H3 148/4885ACACB 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.